Lanreotide Side Effects: Safety Signals and Warnings
Lanreotide safety concerns are compound-specific. The main listed side effects are Diarrhea, Abdominal pain, and Cholelithiasis. The main warning signals are Gallstones - baseline and periodic gallbladder ultrasound, Glucose metabolism alterations - monitor blood glucose in diabetic patients, and Cardiac effects - bradycardia and QT changes reported.
Direct Answer
Lanreotide (Somatuline) is FDA-approved for acromegaly and gastroenteropancreatic NETs, with Phase 3 data including the CLARINET trial showing significant PFS improvement in well-differentiated GEP-NETs. As a deep subcutaneous depot injection, it offers 28-day dosing convenience. A well-validated alternative to octreotide LAR with superior NET data.
- Evidence grade
- Level A
- Research status
- FDA Approved
- Category
- Growth Hormone
- Best for
- Acromegaly, gastroenteropancreatic NETs, somatostatin analog pharmacology, GH/IGF-1 suppression
Reported Side Effects
- Diarrhea
- Abdominal pain
- Cholelithiasis
- Injection site reactions (nodule, pain)
- Nausea
- Flatulence
- Hyperglycemia
Warnings
- Gallstones - baseline and periodic gallbladder ultrasound
- Glucose metabolism alterations - monitor blood glucose in diabetic patients
- Cardiac effects - bradycardia and QT changes reported
- Hypothyroidism with long-term use - monitor thyroid function
Known or Plausible Interactions
- Insulin and oral hypoglycemics (dosage adjustment may be needed)
- Cyclosporine (reduced cyclosporine levels)
- Heart rate-lowering drugs (additive bradycardia)
- QT-prolonging agents (additive QT risk)
Regulatory Context
FDA-approved for acromegaly and unresectable, well- or moderately-differentiated, locally advanced or metastatic GEP-NETs. Available by prescription. Marketed as Somatuline Depot by Ipsen. Extended indication for carcinoid syndrome.
Evidence Snapshot
| Evidence grade | Level A |
|---|---|
| Research status | FDA Approved |
| Best supported outcomes | Acromegaly Biochemical Control (Level A), GEP-NET Tumor Stabilization (Level A), and Gastrointestinal Side Effects (Level A) |
| Primary citation count | 3 |
| Last reviewed | 2026-04-04 |
Related Guides
How to Cite This Page
ExaminePeptides. "Lanreotide Side Effects: Safety Signals and Warnings." Last reviewed 2026-04-04. https://examinepeptides.com/answers/lanreotide-side-effects-safety/
This static answer page is built for fast indexing and direct citation. It summarizes the matching full evidence review and links back to primary sources where the source database includes them.